CRISPR-Cas Genome Editing in <i>Ex Vivo</i> Human Lungs to Rewire the Translational Path of Genome-Targeting Therapeutics-Reference-Cited by-同舟云学术

CRISPR-Cas Genome Editing in Ex Vivo Human Lungs to Rewire the Translational Path of Genome-Targeting Therapeutics

Published:2024-06-01 Issue:11-12 Volume:35 Page:374-387
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Mesaki Kumi¹²^ORCID,Yamamoto Haruchika¹,Juvet Stephen¹²³,Yeung Jonathan¹²⁴,Guan Zehong¹,Akhter Akhi¹,Yao Yan¹,Dickie Cameron¹,Mangat Henna¹,Wang Aizhou¹,Wilson Gavin W.¹⁵,Mariscal Andrea¹,Hu Jim⁶⁷,Davidson Alan R.⁸⁹,Kleinstiver Benjamin P.¹⁰¹¹¹²,Cypel Marcelo¹²,Liu Mingyao¹²⁴,Keshavjee Shaf¹²⁴

Affiliation:

1. Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto, Canada

2. Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

3. Division of Respirology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

4. Division of Thoracic Surgery, Department of Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

5. Department of Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

6. Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

7. Translation Medicine Program, the Hospital for Sick Children, Toronto, Canada

8. Department of Biochemistry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

9. Department of Molecular Genetics, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

10. Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA

11. Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA

12. Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA

Publisher

Mary Ann Liebert Inc

Link

https://www.liebertpub.com/doi/pdf/10.1089/hum.2023.223

Reference45 articles.

1. A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity

2. Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors

3. High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects

4. Rationally engineered Cas9 nucleases with improved specificity

5. Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants